Imatinib mesylate (
Imatinib) is a potent inhibitor of defined
tyrosine kinases and is effectively used for the treatment of
malignancies characterized by the constitutive activation of these
tyrosine kinases, such as
Philadelphia chromosome-positive (Ph(+))
leukemias and
gastrointestinal stromal tumors. Suppressive as well as stimulating effects of this drug on T lymphocytes or dendritic cells (DC), which play a major role in immune
tumor surveillance, have been reported. For this reason, we questioned whether
Imatinib could also affect the phenotypic and functional properties of these subpopulations in Ph(+)
acute lymphoblastic leukemia (ALL) patients on prolonged
Imatinib maintenance treatment. Circulating T lymphocytes and NK cells from
Imatinib-treated Ph(+) ALL patients showed a subset distribution comparable to that of healthy donors. In addition, T-cell immunomodulant
cytokine production (IFN-γ, TNF-α) and proliferative responses were not impaired. A normal monocyte-derived DC differentiation and apoptotic body loading capacity was also observed in the majority of
Imatinib-treated patients. In contrast, an impairment in the DC intracellular production of
IL-12 was recorded, although this was not observed when normal DC were exposed in vitro to
Imatinib. Finally, in vivo
Imatinib treatment did not affect the T-lymphocyte proliferation and IFN-γ production induced by leukemic apoptotic body-loaded DC, underling the potential capability of these cells to generate a specific immune response against tumoral
antigens. Taken together, these findings provide evidence that immunotherapeutic approaches aimed at controlling residual disease in Ph(+) ALL patients in hematologic remission are not jeopardized by the long-term administration of
Imatinib.